<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Summary of the included records</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>No</th>
    <th>Authors, year</th>
    <th>Type of study</th>
    <th>No of Participants</th>
    <th>Intervention</th>
    <th>Time of evaluation</th>
    <th>Outcome</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1</td>
    <td>Cook et al. 2017 [
     <xref ref-type="bibr" rid="CR44">44</xref>]
    </td>
    <td>Randomized clinical trial</td>
    <td>17</td>
    <td>Oral Naltrexone (50 mg) for 4 month</td>
    <td>2, 4 and 7 months</td>
    <td>82% of participants completed the 7-month assessment. Alcohol use was reduced substantially in both groups.</td>
   </tr>
   <tr>
    <td>2</td>
    <td>Edelman et al. 2019 [
     <xref ref-type="bibr" rid="CR45">45</xref>]
    </td>
    <td>Randomized controlled trial</td>
    <td>51</td>
    <td>XR-NTX*, 380 mg (4 mL) injection for 24 weeks</td>
    <td>12, 24,32 and 56 months</td>
    <td>The XR-NTX had no effect on ART adherence and HIV markers. XR-NTX was associated with fewer heavy drinking days.</td>
   </tr>
   <tr>
    <td>3</td>
    <td>Korthuis et al. 2017b [
     <xref ref-type="bibr" rid="CR46">46</xref>]
    </td>
    <td>Pilot study</td>
    <td>29</td>
    <td>XR-NTX injection for 8 month</td>
    <td>16 weeks</td>
    <td>Mean days of drinking to intoxication in the past 30 days was decreased. HIV viral suppression was improved</td>
   </tr>
   <tr>
    <td>4</td>
    <td>Korthuis et al. 2017a [
     <xref ref-type="bibr" rid="CR47">47</xref>]
    </td>
    <td>Pilot/ Feasibility Randomized Trial</td>
    <td>27</td>
    <td>XR-NTX 380 mg for 16 months</td>
    <td>16 weeks</td>
    <td>Mean heavy drinking days was decreased. HIV suppression was improved.</td>
   </tr>
   <tr>
    <td>5</td>
    <td>Springer et al. 2017</td>
    <td>Randomized, double-blind, placebo-controlled trial</td>
    <td>100</td>
    <td>XR-NTX for 6 month</td>
    <td>6 month</td>
    <td>There was no significant differences between groups for drinking outcomes.</td>
   </tr>
   <tr>
    <td>6</td>
    <td>Springer et al. 2018 [
     <xref ref-type="bibr" rid="CR48">48</xref>]
    </td>
    <td>Double blind randomized placebo-controlled trial</td>
    <td>100</td>
    <td>XR-NTX for 6 month</td>
    <td>6 month</td>
    <td>The XR-NTX has improved or maintain the viral suppression (VS).</td>
   </tr>
   <tr>
    <td>7</td>
    <td>Hu et al. 2013 [
     <xref ref-type="bibr" rid="CR49">49</xref>]
    </td>
    <td>Double-blind, randomized controlled trial</td>
    <td>19</td>
    <td>Oral Naltrexone (50 mg) for 4 month</td>
    <td>2, 4 and 7 months</td>
    <td>Average daily alcohol consumption was reduced.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
